The incorporation and metabolism of amyloid-β into chylomicron-like lipid emulsions

Journal of Alzheimer's Disease

Volumn 5, Issue 3, 2003, Pages 179-188

  James, Anthony P ^a   Pal, Sebely ^a   Gennat, Hanni C ^a   Vine, Donna F ^a   Mamo, John C L ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Apolipoproteins; Lipid metabolism

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL ESTER; CHYLOMICRON; IODINE 125; LIPID EMULSION; LIPOPROTEIN; TRACER; TRIACYLGLYCEROL; TRITIUM;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; HUMAN; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN METABOLISM; PROTEIN TRANSPORT; RABBIT;

EID: 0142010615     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2003-5302     Document Type: Article

References (69)

1. N.A. Avdulov, S.V. Chochina, U. Igbavboa, C.S. Warden, A.V. Vassiliev and W.G. Wood, Lipid binding to amyloid betapeptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids, J Neurochem 69 (1997), 1746-1752.
2. C.J. Barrow, A. Yasuda, P.T. Kenny and M.G. Zagorski, Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra, J Mol Biol 225 (1992) 1075-1093.
3. A.L. Biere, B. Ostaszewski, E.R. Stimson, B.T. Hyman, J.E. Maggio and D.J. Selkoe, Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma, J Biol Chem 271 (1996), 32916-32922.
4. A. Bowler, T.G. Redgrave and J.C. Mamo, Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperlipidaemic rabbits is defective. Lack of evidence for an independent chylomicron-remnant receptor, Biochem J 276 (1991), 381-386.
5. J. Carlsson, V.W. Armstrong, H. Reiber, K. Felgenhauer and D. Seidel, Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid, Clin Chim Acta 196 (1991), 167-176.
6. W. Chan, J. Fornwald, M. Brawner and R. Wetzel, Native complex formation between apolipoprotein Eisoforms and the Alzheimer's disease peptide A beta, Biochemistry 35 (1996), 7123-7130.
7. R.H. Christie, M. Freeman and B.T. Hyman, Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease, Am J Pathol 148 (1996), 399-1403.
8. K. Fassbender, M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, H. Runz, S. Kuhl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther and T. Hartmann, Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo, Proc Natl Acad Sci USA, 98 (2001), 5856-5861.
9. T.G. Fletcher and D.A. Keire, The interaction of beta-amyloid protein fragment (12-28) with lipid environments, Protein Sci 6 (1997), 666-675.
10. A.M. Fogelman, B.J. Van Lenten, C. Warden, M.E. Haberland and P.A. Edwards, Macrophage lipoprotein receptors, J Cell Sci Suppl 9 (1988), 135-149.
11. J. Folch, M. Lees and C.H. Sloane-Stanley, A simple method for the isolation and purification of total lipids from animal tissues, J Biol Chem 226 (1957), 17931-17938.
12. E.R. Frears, D.J. Stephens, C.E. Walters, H. Davies and B.M. Austen, The role of cholesterol in the biosynthesis of beta-amyloid, Neuroreport 10 (1999), 1699-1705.
13. J. Ghiso, E. Matsubara, A. Koudinov, N.H. Choi-Miura, M. Tomita, T. Wisniewski and B. Frangione, The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex, Biochem J 293 (1993), 27-30.
14. S.H. Gianturco, A.H. Lin, S.L. Hwang, J. Young, S.A. Brown, D.P. Via and W.A. Bradley, Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins, J Clin Invest 82 (1988), 1633-1643.
15. D. Goldgaber, A.I. Schwarzman, R. Bhasin, L. Gregori, D. Schmechel, A.M. Saunders, A.D. Roses and W.J. Strittmatter, Sequestration of amyloid beta-peptide, Ann N Y Acad Sci 695 (1993), 139-143.
16. C. Hilbich, B. Kisters-Woike, J. Reed, C.L. Masters and K. Beyreuther, Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides, J Mol Biol 228 (1992), 460-473.
17. A. Hofman, A. Ott, M.M. Breteler, M.L. Bots, A.J. Slooter, F. van Harskamp, C.N. van Duijn, C. Van Broeckhoven and D.E. Grobbee, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet 349 (1997), 151-154.
18. M.M. Hussain, R.W. Mahley, J.K. Boyles, P.A. Lindquist, W.J. Brecht and T.L. Innerarity, Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species, J Biol Chem 264 (1989), 17931-17938.
19. N. Ida, T. Hartmann, J. Pantel, J. Schroder, R. Zerfass, H. Forstl, R. Sandbrink, C.L. Masters and K. Beyreuther, Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay, J Biol Chem 271 (1996), 22908-22914.
20. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri and D.A. Drachman, Statins and the risk of dementia, Lancet 356 (2000), 1627-1631.
21. S. Kalmijn, L.J. Launer, A. Ott, J.C. Witteman, A. Hofman and M.M. Breteler, Dietary fat intake and the risk of incident dementia in the Rotterdam Study, Ann Neurol 42 (1997), 776-782.
22. M. Kivipelto, E.L. Helkala, T. Hanninen, M.P. Laakso, M. Hallikainen, K. Alhainen, H. Soininen, J. Tuomilehto and A. Nissinen, Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study, Neurology 56 (2001), 1683-1689.
23. A. Koudinov, E. Matsubara, B. Frangione and J. Ghiso, The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma, Biochem Biophys Res Commun 205 (1994), 1164-1171.
24. A.R. Koudinov, T.T. Berezov and N.V. Koudinova, Alzheimer's amyloid beta and lipid metabolism: a missing link? Faseb J 12 (1998), 1097-1099.
25. A.R. Koudinov, T.T. Berezov, A. Kumar and N.V. Koudinova, Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids, Clin Chim Acta 270 (1998), 75-84.
26. Y.M. Kuo, M.R. Emmerling, C.L. Bisgaier, A.D. Essenburg, H.C. Lampert, D. Drumm and A.E. Roher, Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels, Biochem Biophys Res Commun 252 (1998), 711-715.
27. Y.M. Kuo, M.R. Emmerling, H.C. Lampert, S.R. Hempelman, T.A. Kokjohn, A.S. Woods, R.J. Cotter and A.E. Roher, High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease, Biochem Biophys Res Commun 257 (1999), 787-791.
28. Y.M. Kuo, T.A. Kokjohn, W. Kalback, D. Luehrs, D.R. Galasko, N. Chevallier, E.H. Koo, M.R. Emmerling and A.E. Roher, Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma, Biochem Biophys Res Commun 268 (2000), 750-756.
29. M.J. LaDu, M.T Falduto, A.M. Manelli, C.A. Reardon, G.S. Getz and D.E. Frail, Isoform-specific binding of apolipoprotein E to beta-amyloid, J Biol Chem 269 (1994), 23403-23406.
30. M.J. LaDu, J.R. Lukens, C.A. Reardon and G.S. Getz, Association of human, rat, and rabbit apolipoprotein E with beta-amyloid, J Neurosci Res 49 (1997), 9-18.
31. M.J. LaDu, T.M. Pederson, D.E. Frail, C.A. Reardon, G.S. Getz and M.T. Falduto, Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid, J Biol Chem 270 (1995), 9039-9042.
32. R.W. Mahley, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology, Science 240 (1988), 622-630.
33. R.W. Mahley, Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease, Isr J Med Sci 32 (1996), 414-429.
34. R.W. Mahley and Y. Huang, Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond, Curr Opin Lipidol 10 (1999), 207-217.
35. J.C. Mamo, C.L. Elsegood, Y. Umeda, T. Hirano and T.G. Redgrave, Effect of probucol on plasma clearance and organ uptake of chylomicrons and VLDLs in normal and diabetic rats, Arterioscler Thromb 13 (1993), 231-239.
36. R. Mayeux, M.X. Tang, D.M. Jacobs, J. Manly, K. Bell, C. Merchant, S.A. Small, Y. Stern, H.M. Wisniewski and P.D. Mehta, Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease, Ann Neurol 46 (1999), 412-416.
37. J. Naslund, V. Haroutunian, R. Mohs, K.L. Davis, P. Davies, P. Greengard and J.D. Buxbaum, Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline, Jama 283 (2000), 1571-1577.
38. I.L. Notkola, R. Sulkava, J. Pekkanen, T. Erkinjuntti, C. Ehnholm, P. Kivinen, J. Tuomilehto and A. Nissinen, Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease, Neuroepidemiology 17 (1998), 14-20.
39. I. Osman, O. Gaillard, D. Meillet, M. Bordas-Fonfrede, A. Gervais, E. Schuller, J. Delattre and A. Legrand, A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid. Application to multiple sclerosis and other neurological diseases, Eur J Clin Chem Clin Biochem 33 (1995), 53-58.
40. J. Poirier, J. Davignon, D. Bouthillier, S. Kogan, P. Bertrand and S. Gauthier, Apolipoprotein E polymorphism and Alzheimer's disease, Lancet 342 (1993), 697-699.
41. S.D. Proctor and J.C. Mamo, Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall-evidence that plaque cholesterol may be derived from postprandial lipoproteins, Eur J Clin Invest 28 (1998), 497-503.
42. T.G. Redgrave and R.C. Maranhao, Metabolism of protein-free lipid emulsion models of chylomicrons in rats, Biochim Biophys Acta 835 (1985), 104-112.
43. T.G. Redgrave, D.C. Roberts and C.E. West, Separation of plasma lipoproteins by density-gradient ultracentrifugation, Anal Biochem 65 (1975), 42-49.
44. L.M. Refolo, M.A. Pappolla, B. Malester, J. LaFrancois, T. Bryant-Thomas, R. Wang, G.S. Tint, K. Sambamurti and K. Duff, Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model, Neurobiol Dis 7 (2000), 321-331.
45. S.N. Romas, M.X. Tang, L. Berglund and R. Mayeux, APOE genotype, plasma lipids, lipoproteins, and AD in community elderly, Neurology 53 (1999), 517-521.
46. G. Salen, V. Berginer, V. Shore, I. Horak, E. Horak, G.S. Tint and S. Shefer, Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid, N Engl J Med 316 (1987), 1233-1238.
47. T. Scantlebury, M. Maslowska and K. Cianflone, Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes, J Biol Chem 273 (1998), 20903-20909.
48. H. Scharnagl, U. Tisljar, K. Winkler, M. Huttinger, M.A. Nauck, W. Gross, H. Wieland, T.G. Ohm and W. Marz, The betaA4 amyloid peptide complexes to and enhances the uptake of beta- very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycans pathway, Lab Invest 79 (1999), 1271-1286.
49. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games and P. Seubert, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature 400 (1999), 173-177.
50. D. Scheuner, C. Eckman, M. Jensen, X. Song, M. Citron, N. Suzuki, T.D. Bird, J. Hardy, M. Hutton, W. Kukull, E. Larson, E. Levy-Lahad, M. Viitanen, E. Peskind, P. Poorkaj, G. Schellenberg, R. Tanzi, W. Wasco, L. Lannfelt, D. Selkoe and S. Younkin, Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nat Med 2 (1996), 864-870.
51. A.L. Schwarzman and D. Goldgaber, Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation, Ciba Found Symp 199 (1996), 146-160.
52. J.M. Serot, D. Christmann, T. Dubost and M. Couturier, Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease, J Neurol Neurosurg Psychiatry 63 (1997), 506-508.
53. P. Seubert, C. Vigo-Pelfrey, F. Esch, M. Lee, H. Dovey, D. Davis, S. Sinha, M. Schlossmacher, J. Whaley, C. Swindlehurst and et al., Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids, Nature 359 (1992), 325-327.
54. F.S. Shie, L.W. Jin, D.G. Cook, J.B. Leverenz and R.C. LeBoeuf, Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice, Neuroreport 13 (2002), 455-459.
55. M. Shoji, T.E. Golde, J. Ghiso, T.T. Cheung, S. Estus, L.M. Shaffer, X.D. Cai, D.M. McKay, R. Tintner, B. Frangione and et al., Production of the Alzheimer amyloid beta protein by normal proteolytic processing, Science 258 (1992), 126-129.
56. N. Simionescu and M. Simionescu, Cellular interactions of lipoproteins with the vascular endothelium: endocytosis and transcytosis, Targeted Diagn Ther 5 (1991), 45-95.
57. D. Smith, S.D. Proctor and J.C. Mamo, A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence, Ann Clin Biochem 34 (1997), 185-189.
58. D.L. Sparks, J.C. Hunsaker, 3rd, S.W. Scheff, R.J. Kryscio, J.L. Henson and W.R. Markesbery, Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease, Neurobiol Aging 11 (1990), 601-607.
59. D.L. Sparks, H. Liu, D.R. Gross and S.W. Scheff, Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol, Neurosci Lett 187 (1995), 142-144.
60. W.J. Strittmatter, K.H. Weisgraber, D.Y. Huang, L.M. Dong, G.S. Salvesen, M. Pericak-Vance, D. Schmechel, A.M. Saunders, D. Goldgaber and A.D. Roses, Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease, Proc Natl Acad Sci USA, 90 (1993), 8098-8102.
61. G.R. Thompson, A Handbook of Hyperlipidaemia, Current, London, 1990.
62. T. Wisniewski, A. Golabek, E. Matsubara, J. Ghiso and B. Frangione, Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid, Biochem Biophys Res Commun 192 (1993), 359-365.
63. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia and G. Siegel, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors, Arch Neurol 57 (2000), 1439-1443.
64. K. Yanagisawa, J. McLaurin, M. Michikawa, A. Chakrabartty and Y. Ihara, Amyloid beta-protein (A beta) associated with lipid molecules: immunoreactivity distinct from that of soluble A beta, FEBS Lett 420 (1997), 43-46.
65. D.S. Yang, J.D. Smith, Z. Zhou, S.E. Gandy and R.N. Martins, Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma, J Neurochem 68 (1997), 721-725.
66. K.C. Yu and J.C. Mamo, Chylomicron-remnant-induced foam cell formation and cytotoxicity: a possible mechanism of cell death in atherosclerosis, Clin Sci (Colch) 98 (2000), 183-192.
67. Z. Zhou, J.D. Smith, P. Greengard and S. Gandy, Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E, Mol Med 2 (1996), 175-180.
68. B.V. Zlokovic, Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier, Life Sci 59 (1996), 1483-1497.
69. B.V. Zlokovic, C.L. Martel, J.B. Mackic, E. Matsubara, T. Wisniewski, J.G. McComb, B. Frangione and J. Ghiso, Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta, Biochem Biophys Res Commun 205 (1994), 1431-1437.